The changes from baseline levels of plasmacytoid cells (CD20+/CD138+), SLE B cells (CD19+/CD27BRIGHT/CD38BRIGHT), and plasma cells (CD20−/CD138+) did not show any trend over time in the treatment groups. The gene discussed is CD19; the disease is systemic lupus erythematosus.